April 22 (Reuters) - Abbott Laboratories reported a better-than-expected adjusted quarterly profit, driven by its branded generics, international nutrition and diagnostics divisions.
Sales in the company's division that sells branded generic drugs in emerging markets, jumped 31.8 percent in the first quarter even after including the impact of the strong dollar.
Also read: Mining Companies Are Back in the Black
07:15 Telefonica to sell up to 40 percent of Telxius to KKR for 1.3 billion euros18
09:51 Airbus takes new hit for A400M as core profit beats forecasts15
09:14 Airbus seeks new talks with European nations over A400M costs15
14:29 Unilever rejects $143 billion Kraft Heinz bid as without merit20